Sunday, February 5, 2023
ADVT 
Health

FDA blocks much-anticipated BioMarin hemophilia gene therapy

Darpan News Desk The Canadian Press, 19 Aug, 2020 08:31 PM
  • FDA blocks much-anticipated BioMarin hemophilia gene therapy

Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment.

The U.S. Food and Drug Administration's rejection late Tuesday means the San Rafael, California-based company will have to complete an ongoing late-stage patient study, likely delaying possible approval till late in 2022.

The infused therapy, called Roctavian, could have freed hemophilia A patients from frequent, extremely expensive infusions of a blood-clotting therapy to prevent dangerous internal bleeding. It had been highly anticipated by doctors, patients and investors.

In a statement, BioMarin said the company and the FDA previously agreed on how much patient testing data the agency required to review the therapy, but in its rejection letter the FDA for the first time recommended Biomarin finish the late-stage study and provide two years of follow-up data on the therapy’s safety and efficacy in preventing internal bleeding for all study participants.

The company added that FDA concluded differences between the results of a small, early-stage study and interim data from the late-stage study left unclear how long the therapy’s effect would last.

Roctavian was meant to free patients with severe hemophilia A from 100 to 150 IV infusions of Factor VIII per year to prevent or at least reduce painful, spontaneous bleeding into joints and muscles, which can cause permanent damage to them.

Also known as valoctocogene roxaparvovec or valrox for short, it would have been the first gene therapy approved in the U.S. for any type of hemophilia. That's a rare, genetic bleeding disorder in which people don’t have enough of a clotting protein called Factor VIII due to a mutation in the gene responsible for producing it. They repeatedly suffer spontaneous internal bleeding. About 1 in 10,000 people, mostly males, have hemophilia A, including about 20,000 in the U.S. About half have severe disease.

The gene therapy works by using an inactivated virus, created in a lab, to deliver to liver cells a working gene via a one-time IV infusion meant to enable the body to produce FVIII on its own.

Questions about whether it would work for a lifetime or just a few years came amid rumours that Biomarin might set a price tag as high as $3 million per patient. That would top the price for the most expensive therapy ever approved by the FDA, Swiss drugmaker Novartis AG’s gene therapy for spinal muscular atrophy, Zolgensma, which was launched in spring 2019 with a $2.125 million price tag per patient.

Biomarin has estimated the lifetime cost of current treatments to prevent bleeding at about $25 million, arguing its gene therapy would save far more than its cost.

Several other drugmakers are developing gene therapies for hemophilia A but are further behind in testing: partners Pfizer Inc. and Sangamo Therapeutics, Spark Therapeutics and Generation Bio.

SVB Leerink analyst Joseph Schwartz on Wednesday slashed his 12-month price target for BioMarin's stock from $140 to $113 per share. He called the FDA ruling a “major negative surprise,” but added, “We would not sell the stock here, as disappointing as this is.”

Schwartz noted that after BioMarin disclosed disappointing data from an interim analysis of the ongoing late-stage study, company shares dropped to $63. Schwartz believes BioMarin’s other assets are worth an $88 share price.

The company currently sells six medicines in the U.S., all for rare genetic or enzyme disorders. It posted a profit of $52 million on revenue of $932 million in the first six months of 2020.

In mid-afternoon trading, Biomarin Pharmaceutical Inc. shares plunged $42.62, or 36%, to $75.92. Trading volume by then was about 19 times the usual number of BioMarin shares traded in a day.

MORE Health ARTICLES

Doctors say experimental treatment may have rid man of HIV

Doctors say experimental treatment may have rid man of HIV

A Brazilian man infected with the AIDS virus has shown no sign of it for more than a year since he stopped HIV medicines after an intense experimental drug therapy aimed at purging hidden, dormant virus from his body, doctors reported Tuesday.

Doctors say experimental treatment may have rid man of HIV

AIDS report: Kids are lagging and COVID-19 is harming care

AIDS report: Kids are lagging and COVID-19 is harming care

New numbers on the global AIDS epidemic show some big successes, such as fewer deaths and new infections. But there are also some tragic failures: Only half the children with HIV, the virus that causes the disease, are getting treatment.

AIDS report: Kids are lagging and COVID-19 is harming care

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Dr. Bal Pawa is a uniquely qualified pharmacist and medical doctor. The combined knowledge, plus 3 decades of clinical experience have fuelled her passion to change the way medical care is delivered

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Gilead's $2,340 price for coronavirus drug draws criticism

Gilead's $2,340 price for coronavirus drug draws criticism

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead's $2,340 price for coronavirus drug draws criticism

Serious coronavirus-linked condition hit 285 US children

Serious coronavirus-linked condition hit 285 US children

At least 285 U.S. children have developed a serious inflammatory condition linked to the coronavirus and while most recovered, the potential for long-term or permanent damage is unknown, two new studies suggest.

Serious coronavirus-linked condition hit 285 US children

Tattoo artist sees bump in desire to erase hateful skin art

Tattoo artist sees bump in desire to erase hateful skin art

A Vermont tattoo artist who has long offered free removal or covering of hateful skin art like swastikas, SS lightning bolts or the words “white power” says he’s seen an uptick in business recently following George Floyd's death.

Tattoo artist sees bump in desire to erase hateful skin art